Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors

Cancer Immunology, Immunotherapy

Volumn 60, Issue 10, 2011, Pages 1461-1472

  Thomas, Diana L ^a   Doty, Rosalinda ^a   Tosic, Vesna ^b   Liu, Jia ^c   Kranz, David M ^a   McFadden, Grant ^c   MacNeill, Amy L ^a   Roy, Edward J ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Brain tumor; Melanoma; Myxoma virus; Rapamycin; T cells

Indexed keywords

BETA INTERFERON; BETA INTERFERON ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE; RAPAMYCIN; SERYLISOLEUCYLTYROSYLARGINYLTYROSYLTYROSYLGLYCYLLEUCINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; CANCER RELAPSE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; MYXOMA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYXOMA VIRUS; ONCOLYTIC VIROTHERAPY; SIROLIMUS;

EID: 80054094100     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1045-z     Document Type: Article

References (46)

1. JH Sampson JH Carter Jr AH Friedman HF Seigler 1998 Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma J Neurosurg 88 1 11 20 10.3171/jns.1998.88.1.0011 9420067 10.3171/jns.1998.88.1.0011 1:STN:280:DyaK1c%2FotVagtg%3D%3D (Pubitemid 28018958)
2. SA Rosenberg ME Dudley 2009 Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol 21 2 233 240 10.1016/j.coi.2009.03.002 19304471 10.1016/j.coi.2009.03.002 1:CAS:528:DC%2BD1MXlsVCgtb8%3D
3. ME Dudley JC Yang R Sherry MS Hughes R Royal U Kammula PF Robbins J Huang DE Citrin SF Leitman J Wunderlich NP Restifo A Thomasian SG Downey FO Smith J Klapper K Morton C Laurencot DE White SA Rosenberg 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 32 5233 5239 10.1200/JCO.2008.16.5449 18809613 10.1200/JCO.2008.16.5449 1:CAS:528: DC%2BD1cXhsVyqsrbO
4. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM (2010) Successful Treatment of Melanoma Brain Metastases With Adoptive Cell Therapy. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-10-1507
5. E Jager M Ringhoffer J Karbach M Arand F Oesch A Knuth 1996 Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8 + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo Int J Cancer 66 4 470 476 10.1002/(SICI)1097- 0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C 8635862 10.1002/(SICI)1097- 0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C 1:STN:280: DyaK283htlOrtA%3D%3D (Pubitemid 26178170)
6. A Riker J Cormier M Panelli U Kammula E Wang A Abati P Fetsch KH Lee S Steinberg S Rosenberg F Marincola 1999 Immune selection after antigen-specific immunotherapy of melanoma Surgery 126 2 112 120 S0039606099002044 10455872 10.1016/S0039-6060(99)70143-1 1:STN:280:DyaK1MzosVyitg%3D%3D (Pubitemid 29382769)
7. C Yee JA Thompson D Byrd SR Riddell P Roche E Celis PD Greenberg 2002 Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 99 25 16168 16173 12427970 10.1073/pnas.242600099 1:CAS:528:DC%2BD38Xps1ensLk%3D (Pubitemid 35462767)
8. O Goldberger I Volovitz A Machlenkin E Vadai E Tzehoval L Eisenbach 2008 Exuberated numbers of tumor-specific T cells result in tumor escape Cancer Res 68 9 3450 3457 10.1158/0008-5472.CAN-07-5006 18451173 10.1158/0008-5472.CAN-07- 5006 1:CAS:528:DC%2BD1cXltlSlt78%3D
9. GP Dunn CM Koebel RD Schreiber 2006 Interferons, immunity and cancer immunoediting Nat Rev Immunol 6 11 836 848 10.1038/nri1961 17063185 10.1038/nri1961 1:CAS:528:DC%2BD28XhtFWns7fK (Pubitemid 44631652)
10. JH Sampson GE Archer DA Mitchell AB Heimberger DD Bigner 2008 Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma Semin Immunol 20 5 267 275 18539480 10.1016/j.smim.2008.04.001 1:CAS:528:DC%2BD1cXhtlyhtbfL
11. DL Thomas M Kim NA Bowerman S Narayanan DM Kranz H Schreiber EJ Roy 2009 Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells J Immunol 183 3 1828 1837 10.4049/jimmunol. 0802322 19592642 10.4049/jimmunol.0802322 1:CAS:528:DC%2BD1MXoslCrs74%3D
12. RM Diaz F Galivo T Kottke P Wongthida J Qiao J Thompson M Valdes G Barber RG Vile 2007 Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus Cancer Res 67 6 2840 2848 10.1158/0008-5472.CAN-06-3974 17363607 10.1158/0008-5472.CAN-06-3974 1:CAS:528:DC%2BD2sXivV2nsbs%3D (Pubitemid 46548974)
13. J Qiao H Wang T Kottke RM Diaz C Willmon A Hudacek J Thompson K Parato J Bell J Naik J Chester P Selby K Harrington A Melcher RG Vile 2008 Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors Gene Ther 15 8 604 616 10.1038/sj.gt.3303098 18305577 10.1038/sj.gt.3303098 1:CAS:528: DC%2BD1cXktVGqtLY%3D
14. YQ Zhang YC Tsai A Monie TC Wu CF Hung 2010 Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy Mol Ther 18 4 692 699 10.1038/mt.2009.318 20087318 10.1038/mt.2009.318 1:CAS:528:DC%2BC3cXntVGgug%3D%3D
15. WFJ Sypula Y Ma J Bell G McFadden 2004 Myxoma virus tropism in human tumor cells Gene Ther Mol Biol 8 103 114
16. X Lun W Yang T Alain ZQ Shi H Muzik JW Barrett G McFadden J Bell MG Hamilton DL Senger PA Forsyth 2005 Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas Cancer Res 65 21 9982 9990 16267023 10.1158/0008-5472.CAN-05-1201 1:CAS:528:DC%2BD2MXhtFKktLnK (Pubitemid 41541479)
17. XQ Lun H Zhou T Alain B Sun L Wang JW Barrett MM Stanford G McFadden J Bell DL Senger PA Forsyth 2007 Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin Cancer Res 67 18 8818 8827 17875723 10.1158/0008-5472.CAN-07-1214 1:CAS:528:DC%2BD2sXhtVCit7jI (Pubitemid 47437458)
18. Y Woo KJ Kelly MM Stanford C Galanis YS Chun Y Fong G McFadden 2008 Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells Ann Surg Oncol 15 8 2329 2335 10.1245/s10434-008-9924-z 18454298 10.1245/s10434-008-9924- z
19. Y Wu X Lun H Zhou L Wang B Sun JC Bell JW Barrett G McFadden JA Biegel DL Senger PA Forsyth 2008 Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors Clin Cancer Res 14 4 1218 1227 10.1158/1078-0432.CCR-07-1330 18281557 10.1158/1078-0432.CCR-07- 1330 1:CAS:528:DC%2BD1cXhvF2ntro%3D (Pubitemid 351302571)
20. M Kim GJ Madlambayan MM Rahman SE Smallwood AM Meacham K Hosaka EW Scott CR Cogle G McFadden 2009 Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells Leukemia 23 12 2313 2317 10.1038/leu.2009.219 19865109 10.1038/leu.2009.219 1:STN:280:DC%2BD1MfivV2rtg%3D%3D
21. MM Stanford M Shaban JW Barrett SJ Werden PA Gilbert J Bondy-Denomy L Mackenzie KC Graham AF Chambers G McFadden 2008 Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo Mol Ther 16 1 52 59 17998900 10.1038/sj.mt.6300348 1:CAS:528:DC%2BD2sXhsVKkurfP
22. X Lun T Alain FJ Zemp H Zhou MM Rahman MG Hamilton G McFadden J Bell DL Senger PA Forsyth 2010 Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin Cancer Res 70 2 598 608 10.1158/0008-5472.CAN-09-1510 20068158 10.1158/0008-5472.CAN-09-1510 1:CAS:528:DC%2BC3cXltlWruw%3D%3D
23. G McFadden 2005 Poxvirus tropism Nat Rev Microbiol 3 3 201 213 10.1038/nrmicro1099 15738948 10.1038/nrmicro1099 1:CAS:528:DC%2BD2MXhslGjtLk%3D (Pubitemid 40298220)
24. EW Jackson CR Dorn JK Saito DG McKercher 1966 Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis Nature 211 5046 313 314 4381646 10.1038/211313a0 1:STN:280:DyaF2s7mt1Gkuw%3D%3D
25. K Homicsko A Lukashev RD Iggo 2005 RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer Cancer Res 65 15 6882 6890 10.1158/0008-5472.CAN-05-0309 16061672 10.1158/0008-5472.CAN-05-0309 1:CAS:528:DC%2BD2MXmvFSlur4%3D (Pubitemid 41060727)
26. MM Alonso C Gomez-Manzano H Jiang NB Bekele Y Piao WK Yung R Alemany J Fueyo 2007 Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo Cancer Gene Ther 14 8 756 761 10.1038/sj.cgt.7701067 17557108 10.1038/sj.cgt.7701067 1:CAS:528: DC%2BD2sXnvVelsLg%3D (Pubitemid 47080367)
27. MM Alonso H Jiang T Yokoyama J Xu NB Bekele FF Lang S Kondo C Gomez-Manzano J Fueyo 2008 Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death Mol Ther 16 3 487 493 10.1038/sj.mt.6300400 18253154 10.1038/sj.mt.6300400 1:CAS:528: DC%2BD1cXisFOrsrw%3D (Pubitemid 351314987)
28. XQ Lun JH Jang N Tang H Deng R Head JC Bell DF Stojdl CL Nutt DL Senger PA Forsyth JA McCart 2009 Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide Clin Cancer Res 15 8 2777 2788 10.1158/1078-0432.CCR-08-2342 19351762 10.1158/1078-0432.CCR-08-2342 1:CAS:528:DC%2BD1MXksV2ntr4%3D
29. T Alain X Lun Y Martineau P Sean B Pulendran E Petroulakis FJ Zemp CG Lemay D Roy JC Bell G Thomas SC Kozma PA Forsyth M Costa-Mattioli N Sonenberg 2010 Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production Proc Natl Acad Sci USA 107 4 1576 1581 10.1073/pnas.0912344107 20080710 10.1073/pnas.0912344107 1:CAS:528: DC%2BC3cXhslOrs7Y%3D
30. X Lun J Chan H Zhou B Sun JJ Kelly OO Stechishin JC Bell K Parato K Hu D Vaillant J Wang TC Liu C Breitbach D Kirn DL Senger PA Forsyth 2010 Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma Mol Ther 18 11 1927 1936 10.1038/mt.2010.183 20808290 10.1038/mt.2010.183 1:CAS:528:DC%2BC3cXhtVyqsL%2FM
31. C Blank I Brown AC Peterson M Spiotto Y Iwai T Honjo TF Gajewski 2004 PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells Cancer Res 64 3 1140 1145 14871849 10.1158/0008-5472.CAN-03-3259 1:CAS:528:DC%2BD2cXhtFCgtrs%3D (Pubitemid 38176921)
32. J Liu S Wennier M Reinhard E Roy A MacNeill G McFadden 2009 Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits J Virol 83 11 5933 5938 10.1128/JVI.00204-09 19279088 10.1128/JVI.00204-09 1:CAS:528:DC%2BD1MXmtlGktrw%3D
33. B Zhang NA Bowerman JK Salama H Schmidt MT Spiotto A Schietinger P Yu YX Fu RR Weichselbaum DA Rowley DM Kranz H Schreiber 2007 Induced sensitization of tumor stroma leads to eradication of established cancer by T cells J Exp Med 204 1 49 55 17210731 10.1084/jem.20062056 1:CAS:528:DC%2BD2sXhtFGjsbY%3D (Pubitemid 46148755)
34. T Calzascia W Di Berardino-Besson R Wilmotte F Masson N de Tribolet PY Dietrich PR Walker 2003 Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain J Immunol 171 5 2187 2191 12928361 1:CAS:528:DC%2BD3sXmsVOrsLc%3D (Pubitemid 37025522)
35. J Kline IE Brown YY Zha C Blank J Strickler H Wouters L Zhang TF Gajewski 2008 Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma Clin Cancer Res 14 10 3156 3167 10.1158/1078-0432. CCR-07-4696 18483384 10.1158/1078-0432.CCR-07-4696 1:CAS:528: DC%2BD1cXmtVCmurg%3D
36. CD Surh J Sprent 2008 Homeostasis of naive and memory T cells Immunity 29 6 848 862 10.1016/j.immuni.2008.11.002 19100699 10.1016/j.immuni.2008.11.002 1:CAS:528:DC%2BD1MXhtlynuw%3D%3D
37. Q Ge H Hu HN Eisen J Chen 2002 Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments Proc Natl Acad Sci USA 99 5 2989 2994 10.1073/pnas. 05271409999/5/2989 11880642 10.1073/pnas.052714099 1:CAS:528: DC%2BD38Xit1Cru74%3D (Pubitemid 34240573)
38. F Wang Y Ma JW Barrett X Gao J Loh E Barton HW Virgin G McFadden 2004 Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier Nat Immunol 5 12 1266 1274 15502830 10.1038/ni1132 1:CAS:528:DC%2BD2cXpvV2rsLk%3D (Pubitemid 41057742)
39. E Bartee MR Mohamed MC Lopez HV Baker G McFadden 2009 The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts J Virol 83 2 498 511 10.1128/JVI.01376-08 18971273 10.1128/JVI.01376-08 1:CAS:528: DC%2BD1MXotlCmsL0%3D
40. M Fujita ME Scheurer SA Decker HA McDonald G Kohanbash ER Kastenhuber H Kato ML Bondy JR Ohlfest H Okada 2010 Role of type 1 IFNs in antiglioma immunosurveillance-using mouse studies to guide examination of novel prognostic markers in humans Clin Cancer Res 16 13 3409 3419 10.1158/1078-0432.CCR-10-0644 20472682 10.1158/1078-0432.CCR-10-0644 1:CAS:528:DC%2BC3cXot1Wltr8%3D
41. CL Willmon V Saloura ZG Fridlender P Wongthida RM Diaz J Thompson T Kottke M Federspiel G Barber SM Albelda RG Vile 2009 Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma Cancer Res 69 19 7713 7720 10.1158/0008-5472.CAN-09-1013 19773437 10.1158/0008-5472.CAN-09-1013 1:CAS:528:DC%2BD1MXht1Skt7jK
42. B Xu D Grander O Sangfelt S Einhorn 1994 Primary leukemia cells resistant to alpha-interferon in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3 Blood 84 6 1942 1949 8080997 1:STN:280:DyaK2czmt1antw%3D%3D (Pubitemid 24286146)
43. LH Wong KG Krauer I Hatzinisiriou MJ Estcourt P Hersey ND Tam S Edmondson RJ Devenish SJ Ralph 1997 Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma J Biol Chem 272 45 28779 28785 9353349 10.1074/jbc.272.45.28779 1:CAS:528:DyaK2sXntlGhsLc%3D (Pubitemid 27517837)
44. GP Dunn KC Sheehan LJ Old RD Schreiber 2005 IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression Cancer Res 65 8 3447 3453 10.1158/0008-5472.CAN-04-4316 15833880 1:CAS:528:DC%2BD2MXjt1yrtr0%3D (Pubitemid 40524631)
45. MM Stanford JW Barrett SH Nazarian S Werden G McFadden 2007 Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells J Virol 81 3 1251 1260 17108021 10.1128/JVI.01408-06 1:CAS:528:DC%2BD2sXhtFCgurk%3D (Pubitemid 46167846)
46. K Araki AP Turner VO Shaffer S Gangappa SA Keller MF Bachmann CP Larsen R Ahmed 2009 mTOR regulates memory CD8 T-cell differentiation Nature 460 7251 108 112 10.1038/nature08155 19543266 10.1038/nature08155 1:CAS:528: DC%2BD1MXnsFSit78%3D